Karin Agerman - Combigene Chief Officer
| COMBI Stock | SEK 2.36 0.20 7.81% |
Insider
Karin Agerman is Chief Officer of Combigene AB
| Age | 50 |
| Phone | 46 7 04 66 31 63 |
| Web | https://www.combigene.com |
Combigene Management Efficiency
The company has return on total asset (ROA) of 0.2071 % which means that it generated a profit of $0.2071 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4774 %, meaning that it generated $0.4774 on every $100 dollars invested by stockholders. Combigene's management efficiency ratios could be used to measure how well Combigene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Henrik MSc | Bavarian Nordic | 58 | |
| Christopher Bird | BioPorto | N/A | |
| Rolf Srensen | Bavarian Nordic | N/A | |
| Neil CPA | BioPorto | 55 | |
| Laurence Moerlooze | Bavarian Nordic | 59 | |
| Russell Thirsk | Bavarian Nordic | N/A | |
| Lars Uttenthal | BioPorto | N/A | |
| Paul MSc | Bavarian Nordic | 56 | |
| Niels Kristensen | cBrain AS | N/A | |
| Nis Kruse | BioPorto | N/A | |
| Anthony Pare | BioPorto | 60 | |
| Gry Larsen | BioPorto | N/A | |
| Ejvindgensen | cBrain AS | N/A | |
| JeanChristophe May | Bavarian Nordic | 56 | |
| Anu Kerns | Bavarian Nordic | 51 | |
| Tony Summerlin | cBrain AS | N/A | |
| Jennifer Zonderman | BioPorto | N/A | |
Management Performance
| Return On Equity | 0.48 | |||
| Return On Asset | 0.21 |
Combigene AB Leadership Team
Elected by the shareholders, the Combigene's board of directors comprises two types of representatives: Combigene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Combigene. The board's role is to monitor Combigene's management team and ensure that shareholders' interests are well served. Combigene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Combigene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jan Nilsson, Chief Officer | ||
| Louise Aspenberg, Chief Officer | ||
| Associate Woldbye, Scientific Founder | ||
| Pr Kokaia, Scientific Founder | ||
| Karin Agerman, Chief Officer | ||
| Peter Ekolind, Chief Officer |
Combigene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Combigene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.48 | |||
| Return On Asset | 0.21 | |||
| Profit Margin | 0.59 % | |||
| Operating Margin | 0.42 % | |||
| Current Valuation | 125.36 M | |||
| Shares Outstanding | 19.8 M | |||
| Shares Owned By Insiders | 31.29 % | |||
| Shares Owned By Institutions | 1.41 % | |||
| Price To Book | 1.06 X | |||
| Price To Sales | 1.62 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Combigene Stock Analysis
When running Combigene's price analysis, check to measure Combigene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Combigene is operating at the current time. Most of Combigene's value examination focuses on studying past and present price action to predict the probability of Combigene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Combigene's price. Additionally, you may evaluate how the addition of Combigene to your portfolios can decrease your overall portfolio volatility.